Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A

Antihemophilic factor (recombinant) (rAHF; ADVATE(®); Baxalta US Inc., a Takeda company, Lexington, MA, USA) is indicated for the treatment and prevention of bleeding in patients with hemophilia A. We aimed to assess the safety and efficacy of standard prophylaxis versus on-demand treatment with rAH...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yongqiang, Hu, Yu, Jin, Jie, Zhao, Xielan, Wang, Xuefeng, Wu, Runhui, Wu, Depei, Yang, Renchi, Yang, Feng’e, Hu, Qun, Wang, Juan, Fang, Hai, Engl, Werner
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890741/
https://www.ncbi.nlm.nih.gov/pubmed/33587652
http://dx.doi.org/10.1177/1076029621989811

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7890741/
https://www.ncbi.nlm.nih.gov/pubmed/33587652
http://dx.doi.org/10.1177/1076029621989811

Ejemplares similares